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Abstract: The complement system is associated with various diseases such as inflammation or
auto-immune diseases. Complement-targeted drugs could provide novel therapeutic intervention
against the above diseases. C1s, a serine protease, plays an important role in the CS and could be an
attractive target since it blocks the system at an early stage of the complement cascade. Designing
C1 inhibitors is particularly challenging since known inhibitors are restricted to a narrow bioactive
chemical space in addition selectivity over other serine proteases is an important requirement.
The typical architecture of a small molecule inhibitor of C1s contains an amidine (or guanidine)
residue, however, the discovery of non-amidine inhibitors might have high value, particularly if
novel chemotypes and/or compounds displaying improved selectivity are identified. We applied
various virtual screening approaches to identify C1s focused libraries that lack the amidine/guanidine
functionalities, then the in silico generated libraries were evaluated by in vitro biological assays.
While 3D structure-based methods were not suitable for virtual screening of C1s inhibitors, and a 2D
similarity search did not lead to novel chemotypes, pharmacophore model generation allowed us to
identify two novel chemotypes with submicromolar activities. In three screening rounds we tested
altogether 89 compounds and identified 20 hit compounds (<10 µM activities; overall hit rate: 22.5%).
The highest activity determined was 12 nM (1,2,4-triazole), while for the newly identified chemotypes
(1,3-benzoxazin-4-one and thieno[2,3-d][1,3]oxazin-4-one) it was 241 nM and 549 nM, respectively.
Keywords: complement system; virtual screening; C1s inhibitor; FactorXa; biological screening;
pharmacophore modelling
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1. Introduction
In our drug discovery project our objective was to identify potential C1s inhibitors, preferably
having novel chemotypes as well as with acceptable selectivity over related serine proteases.
The complement system (CS) is a key component of innate immunity, which is involved in several
physiological and pathological processes. Dysregulated or impaired complement is involved in an
increasing list of human diseases (e.g., autoimmune, inflammatory, and neurodegenerative diseases
etc.). CS consists of over forty protein components that are present in the blood or on cell surfaces.
The CS is activated by infection or by injury. Activation may be prolonged or misdirected to healthy cells
and can lead to inflammatory or auto-immune diseases. Complement-targeted drugs could provide
novel therapeutic intervention against the above diseases. Nine serine proteases are integral elements
of the CS cascade (C1r, C1s, C2, MASP-1, MASP-2, MASP-3, factor D, factor B, factor I–Scheme 1).
C1s is present as a proenzyme within the C1 complex, the first component of the CS consisting of a
C1q, two C1r and two C1s molecules. The activation of the C1 complex is the first step of the classical
activation pathway of CS, which is initiated by the interaction of C1q with immunoglobulin (Ig) antigen
complexes. The activation signal is mechanically transmitted by C1q to C1r dimers; activated C1r
proteases then cleave and activate the C1s proenzymes. Activated C1s protease forwards the activation
signal by cleaving C4 and C4b-associated C2 to form C3 convertase C4b2a, so an inhibitor that targets
the C1s protease domain could block the activation of the classical pathway of CS [1,2].
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architecture of a small molecule inhibitor of C1s contains a heterocyclic amidine (or guanidine),
such as nafamostat (FUT175) [4], which inhibits several serine proteases, thus, it is uncertain that
its physiological effects are associated with the complement system. Janssen researchers reported
arylsulfonylthiophene-2-carboxamidine inhibitors [5–7] that exhibited somewhat improved selectivity.
Due to poor pharmacokinetics, introduction of pegylated linkers led to related compounds with good
potency and in vivo pharmacokinetic properties [8]. Recently, various inhibitors lacking the amidine
(guanidine) “warheads” were identified by HTS technologies (Molecular Library Screening Center
Network (MLSCN); Penn Center for Molecular Discovery (PCMD); listed in PubChem) [9,10] and
reported by Chen et al. [11]. Due to the limited availability of the amidine and guanidine derivatives
from commercial repositories we have chosen the reported O, N-heterocycles (lacking the “warheads”)
and the potential bioisosteric replacements of amidine (guanidine) motifs as starting points for selecting
C1s focused compound libraries.
Over the past two decades huge compound repositories were built exploiting historical collections
as well as compound libraries. At the same time the chemoinformatics methods have developed
rapidly, the computational power increased allowing fast or real time calculations. In addition,
deeper knowledge has gathered about the small molecule–protein interactions using state-of-the-art
X-ray crystallography, docking and 3D modelling [12]. In our efforts to identify novel C1s inhibitors
we intended to use this huge available commercial chemical space and virtual screening (VS) using
various approaches (2D similarity search, 3D modelling and pharmacophore model building).
Virtual screening leading to focused libraries has become a popular technique [13] since it was
expected to reduce the synthesis and biological screening cost and shortens the life cycles of the
discovery phases. Furthermore, focused library screening often results in many fold increases in the
hit rate compared with random screening of commercial libraries [14,15].
From its emergence vs. combined 2D/3D ligand-based and structure-based approaches [16,17].
The overall size of the existing compound collection is estimated over 35M based on the Zinc
library [18,19]. eMolecules [20] contains 7 million commercially available, unique structures from
various library providers. In our library selection process, we used a 5 million collection of commercially
available compounds collected from the most relevant suppliers [21–28].
Measuring the C1s inhibitory activity we adapted a photometric and fluorescent assay and
validated the assay with known C1s inhibitors. The protein was expressed in a bacterial system.
For considering selectivity of the tested C1s inhibitors, Factor Xa—a key component of the
coagulation cascade—was selected. Coagulation or clotting system is an analog serine protease cascade,
regarding numerous serine protease elements, various pathways of activation, multiple points of
regulation, with a potential amplification loop. Factor Xa is an activated form of Factor X, a key
component of the coagulation system, a trypsin-like serine protease holding a central position that
links the intrinsic and extrinsic activation pathways. FXa is similar to C1s considering its modular
nature; activation by site-specific cleavage; containing a serine protease (SP) domain with strikingly
similar binding sub-sites, however, in C1s large insertion yields higher degree of selectivity with
concomitant decrease in activity [29,30]. Furthermore, C1s and Factor Xa have similar active site
substrate specificity [31,32].
2. Results
2.1. Generation of C1s Inhibitor Focused Library (by 2D Methods)
We first collected known C1s inhibitors from PubChem and available publications, as well as
generated the bioisosters of the key recognition motifs (guanidine, amidine). Based on the resulting
novel structural motifs and the structure of the known inhibitors (“Search patterns”) a focused library
was selected from commercial vendor libraries (5 million compounds, “Target database”) upon 2D
structural similarities (Scheme 2).
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Scheme 2. Flow chart of the focused library generation by 2D similarity search.
Known C1s inhibitors that lack the amidine/guanidine moieties were identified in PubChem and
selected publications. After clustering the various inhibitors that have low µM inhibitory activities,
and removing the redundant structures eight amidine/guanidine and 12 non-amidine/guanidine
compounds were selected as seed/reference compounds for 2D similarity search (Supplementary
Materials Table S1a,b).
For generating the bioisosteric replacements of the amidine and guanidine recognition motifs we
applied literature sources [33] and software [34] (30 selected bioisosteric transformations can be found:
Supplementary Materials, Scheme S1). Relatively few compounds (1100) were found in the vendor
databases that contained the generated bioisosteric replacements and those compounds were also
used for similarity search matching their structures with the reference compounds. The two searches
resulted in 4667 compounds applying T ≥ 0.65 Tanimoto coefficient as a similarity cut-off value.
Virtual focused library generation is often linked to target families that represent a distinct
chemical, biological and property space [35]. Several target families have a different property range,
therefore, defining a target-specific parameter space is often more practical for focused library filtering
than applying the standard Lipinski’s Rule of 5-based filtering [36]. Those rules propose general limits
(cut-off values and ranges) for library filtering and represent a parameter “window” favorable for
oral administration.
Physico-chemical parameter determination of the known C1s inhibitors are the following (amidines,
guanidines were excluded): Mol. weight = 213–358 Da; LogP = 1.67–4.15; tPsa = 35 – 80 Å2; H-bond
acceptor = 2–5; H bond donor = 0–1; rotatable bond = 1–5. Thus, the initial C1s focused library
was filtered for the above physico-chemical parameter space of the known inhibitors leading to
206 structures. Finally, 50 compounds were selected for purchase based on cluster representation
and diversity.
2.2. Generation of C1s Inhibitor Focused Library (Pharmacophore Search Methods)
Physico-chemical parameter space filte ing of the 5 million compound vendor libraries applying the
previously identified ranges except the molecular weight range was set wider (200–450 Da); removal of
the duplicated structures resulted in 445,457 compounds (Enamine (71,311 compounds), ChemDiv
(258,797 compounds), Chembridge (60,052 compounds), Interbioscreen (31,255 compounds) and Life
Chemicals (24,042 compounds). In the next stage, phase database creator (including ligand preparation
up to 100 conformers and stereoisomers ionization and tautomers) was used to develop pharmacophore
libraries leading to 679,420 structures that were used as entries in the pharmacophore-based virtual
Molecules 2019, 24, 3641 5 of 29
screening (Scheme 3). The virtual screening was carried out by the three major clusters representing the
2D focused library screening hits (1,2,3-benzotriazoles, 1,2,4-triazoles, 3,1-benzoxazin-4-one) applying
the best models selected for each cluster.
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each (3 × 50).
Cluster I contains compounds having the highest phase score ranges coming from the
3,1-benzoxazin-4-one-based pharmacophore model (best 50: 2.94–2.55); Cluster II. contains compounds
having the highest phase score ranges coming from the 1,2,3-benzotriazole model (best 50: 2.81–2.35);
while Cluster III contains the compounds having the highest phase score ranges coming from
1,2,4-triazole model (best 50: 2.54–2.32). Based on the phase scores and maintaining the maximum
structural diversity we selected 21 compounds for biological screening (nine compounds from the best
model for 3,1-benzoxazin-4-one; seven compounds from the best model for 1,2,3-benzotriazole and
five c mpounds from the best m del for: 1,2,4-triazole).
2.3. Generation of C1s Inhibitor Hit-Validation Small Library
For hit validation 11 thieno[2,3-d][1,3]oxazin-4-ones and seven 1,3-benzoxazin-4-one derivatives
were selected as close analogues of the pharmacophore hit compounds from commercial databases.
A simple substructure search resulted in ca. 350 compounds having the thieno[2,3-d][1,3]oxazin-4-one
core and only 50 compounds containing the 1,3-benzoxazin-4-one scaffold. Based on the substitution
pattern of the hit compounds the close analogues were selected by visual structural analysis.
2.4. In Vitro Screening Results
2.4.1. C1s Inhibition
Tables 1–5. shows the C1s inhibitory activities according to the 5 chemotypes: 1,2,3-benzotriazoles
(Table 1); 1,2,4-triazoles (Table 2); 3,1-benzoxazin-4-ones (Table 3); thieno[2,3-d][1,3]oxazin-4-one
(Table 4); 1,3-benzoxazin-4-one (Table 5).
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Table 1. Hit compounds derived from the 1,2,3-benzotriazole chemotype. We considered hits if the inhibitory activity was <10 µM. In some cases we display
compounds with weak activities (≤50 µM; in italics).
Entry Structure IDNUMBER IC50 C1s; µM LogP TPSA H Bond Acceptors H Bond Donors Rotatable Bonds Lipinski Rule of 5 (4 of 4) Chemoinformatics
1
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Table 1. Hit compounds derived from the 1,2,3-benzotriazole chemotype. We considered hits if the 
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01365717 
2.4 2.97 86.97 5 0 7 true 2D similarity 
Table 3. Hit compounds derived from the 3,1-benzoxazin-4-one chemotype. 
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µM 
LogP TPSA 
H bond 
Acceptors 
H 
Bond 
Donors 
Rotatable 
Bonds 
Lipinski 
rule of 5 
(4 of 4) 
Chemoinformatics 
13 3226-0357 0.474 3.02 51.80 2 0 1 true Pharmacophore 
14 Z55930777 6.44 2.10 70.26 4 0 3 true Pharmacophore 
15 
BAS 
01170083 
6.7 3.02 51.80 2 0 1 true 2D similarity 
16 
4334-1472 
(CHEMBL-
1449374 
29 2.02 78.10 3 0 3 true 2D similarity 
Table 4. Hit compounds derived from the thieno[2,3-d][1,3]oxazin-4-one chemotype. 
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H bond 
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Chemoinformatics 
17 
STOCK1S-
76323 
(CHEMBL-
1333976) 
0.549 3.52 51.80 2 0 1 true Pharmacophore 
BAS 07161957
(CHEMBL-490106) 0.012 3. 5 70.15 4 0 4 true 2D similarity
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14 Z55930777 6.44 2.10 70.26 4 0 3 true Pharmacophore 
15 
BAS 
01170083 
6.7 3.02 51.80 2 0 1 true 2D similarity 
16 
4334-1472 
(CHEMBL-
1449374 
29 2.02 78.10 3 0 3 true 2D similarity 
Table 4. Hit compounds derived from the thieno[2,3-d][1,3]oxazin-4-one chemotype. 
Entry Structure IDNUMBER 
IC50 
C1s; 
µM 
LogP TPSA 
H bond 
Acceptors 
H 
Bond 
Donors 
Rotatable 
Bonds 
Lipinski 
Rule of 5 
(4 of 4) 
Chemoinformatics 
17 
STOCK1S-
76323 
(CHEMBL-
1333976) 
0.549 3.52 51.80 2 0 1 true Pharmacophore 
STOCK1S-76323
(CHEMBL-1333976) 0.549 3.52 51.80 2 0 1 true Pharmacophore
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18 
STOCK3S-
12710 
(CHEMBL-
1501165) 
0.845 4.72 38.66 2 0 1 true Hit validation 
19 
STOCK2S-
97295 
(CHEMBL-
1441606) 
~20 4.46 38.66 2 0 1 true Hit validation 
20 
STOCK2S-
12571 
~50 4.98 38.66 2 0 1 true Hit validation 
Table 5. Hit compounds derived from the 1,3-benzoxazin-4-one chemotype. 
Entry Structure IDNUMBER 
IC50 
C1s; 
µM 
LogP TPSA 
H bond 
acceptors 
H bond 
donors 
Rotatable 
bonds 
Lipinski 
rule of 5 
(4 of 4) 
Chemoinformatics 
21 Z55992821 0.241 3.20 38.66 2 0 1 true Pharmacophore 
22 Z55992803 3.6 2.35 51.80 2 0 1 true Hit validation 
23 Z55992807 41 2.26 51.80 2 0 1 true Hit validation 
2.4.2. Factor Xa Inhibition 
Out of the 20 C1s hit compounds 6 compounds exhibited significant selectivities towards C1s 
(Table 6., remaining activities are > 85% in the Factor Xa assay). 
Table 6. Factor Xa inhibition of the 20 C1s inhibitor hit compounds. (Compounds with remaining 
activities >80 % are shown in bold). 
Entry Factor Xa 10µM Remaining Activity % Entry Factor Xa 10µM Remaining Activity % 
1 30.3 11 26.02 
2 43.1 12 85.4 
3 4.93 13 98.6 
4 86.2 14 61.4 
5 48.3 15 82 
6 92.3 16 77.6 
7 92.1 17 100 
8 76.5 18 46.1 
9 2.39 21 53.6 
10 78.1 22 0.14 
STOCK3S-12710
(CHEMBL-1501165) 0.845 4.72 38.66 2 0 1 true Hit validation
19
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bonds 
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rule of 5 
(4 of 4) 
Chemoinformatics 
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6 92.3 16 77.6 
7 92.1 17 100 
8 76.5 18 46.1 
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Table 5. Hit compounds derived from the 1,3-benzoxazin-4-one chemotype. 
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IC50 
C1s; 
µM 
LogP TPSA 
H bond 
acceptors 
H bond 
donors 
Rotatable 
bonds 
Lipinski 
rule of 5 
(4 of 4) 
Chemoinformatics 
21 Z55992821 0.241 3.20 38.66 2 0 1 true Pharmacophore 
22 Z55992803 3.6 2.35 51.80 2 0 1 true Hit validation 
23 Z55992807 41 2.26 51.80 2 0 1 true Hit validation 
2.4.2. Factor Xa Inhibition 
Out of the 20 C1s hit compounds 6 compounds exhibited significant selectivities towards C1s 
(Table 6., remaining activities are > 85% in the Factor Xa assay). 
Table 6. Factor Xa inhibition of the 20 C1s inhibitor hit compounds. (Compounds with remaining 
activities >80 % are shown in bold). 
Entry Factor Xa 10µM Remaining Activity % Entry Factor Xa 10µM Remaining Activity % 
1 30.3 11 26.02 
2 43.1 12 85.4 
3 4.93 13 98.6 
4 86.2 14 61.4 
5 48.3 15 82 
6 92.3 16 77.6 
7 92.1 17 100 
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Table 5. Hit compounds derived from the 1,3-benzoxazin-4-one chemotype.
Entry Structure IDNUMBER IC50 C1s; µM LogP TPSA H Bond Acceptors H Bond Donors Rotatable Bonds Lipinski Rule of 5 (4 of 4) Chemoinformatics
21
Molecules 2019, 24, 3641 8 of 28 
18 
STOCK3S-
12710 
(CHEMBL-
1501165) 
0.845 4.72 38.66 2 0 1 true Hit validation 
19 
STOCK2S-
97295 
(CHEMBL-
1441606) 
~20 4.46 38.66 2 0 1 true Hit validation 
20 
STOCK2S-
12571 
~50 4.98 38.66 2 0 1 true Hit validation 
Table 5. Hit compounds derived from the 1,3-benzoxazin-4-one chemotyp . 
Entry Struct re IDNUMBER 
IC50 
C1s; 
µM 
LogP TPSA 
H bond 
acceptors 
H bond 
donors 
Rotatable 
bonds 
Lipinski 
rule of 5 
(4 of 4) 
Chemoinformatics 
21 Z55992821 0.241 3.20 38.66 2 0 1 true Pharmacophore 
22 Z55992803 3.6 2.35 51.80 2 0 1 true Hit validation 
23 Z55992807 41 2.26 51.80 2 0 1 true Hit validation 
2.4.2. Factor Xa I hibition 
Out of the 20 C1s h  compounds 6 compounds exhibited significant selectivities towards C1s 
(Table 6., remaining activities are > 85% in the Factor Xa assay). 
Table 6. Factor Xa inhibit on f the 20 C1s inhibitor hit compounds. (Compounds with remaining 
activities >80 % are shown in bold). 
Entry Factor Xa 10µM Remaining Activity % Entry Factor Xa 10µM Remaining Activity % 
1 30.3 11 26.02 
2 43.1 12 85.4 
3 4.93 13 98.6 
4 86.2 14 61.4 
5 48.3 15 82 
6 92.3 16 77.6 
7 92.1 17 100 
8 76.5 18 46.1 
9 2.39 21 53.6 
10 78.1 22 0.14 
Z55992821 0.241 3.20 38.66 2 0 1 true Pharmacophore
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18 
STOCK3S-
12710 
(CHEMBL-
1501165) 
0.845 4.72 38.66 2 0 1 true Hit validation 
19 
STOCK2S-
97295 
(CHEMBL-
1441606) 
~20 4.46 38.66 2 0 1 true Hit validation 
20 
STOCK2S-
12571 
~50 4.98 38.66 2 0 1 true Hit validation 
Table 5. Hit compounds derived from the 1,3-be zoxazin-4-one chemotype. 
Entry Structure IDNUMBER 
IC50 
C1s; 
µM 
LogP TPSA 
H bond 
acceptors 
H bond 
donors 
Rotatable 
bonds 
Lipinski 
rule of 5 
(4 of 4) 
Chemoinformatics 
21 Z55992821 0.241 3.20 38.66 2 0 1 true Pharmacophore 
22 Z55992803 3.6 2.35 51.80 2 0 1 true Hit validation 
23 Z55992807 41 2.26 51.80 2 0 1 true Hit validation 
2.4.2. Factor Xa I hibition 
Out of the 20 C1s hit compounds 6 compounds exhibited significant selectivities towards C1s 
(Table 6., remaining activities are > 85% in the Factor Xa assay). 
Table 6. Factor Xa inhibition of the 20 C1s inhibitor hit compounds. (Compounds with remaining 
activities >80 % are shown in bold). 
Entry Factor Xa 10µM Remaining Activity % Entry Factor Xa 10µM Remaining Activity % 
1 30.3 11 26.02 
2 43.1 12 85.4 
3 4.93 13 98.6 
4 86.2 14 61.4 
5 48.3 15 82 
6 92.3 16 77.6 
7 92.1 17 100 
8 76.5 18 46.1 
9 2.39 21 53.6 
10 78.1 22 0.14 
Z55992803 3.6 2.35 51.80 2 0 1 true Hit validation
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18 
STOCK3S-
127 0 
(CHEMBL-
1501165) 
0.845 4.72 38.66 2 0 1 true Hit validation 
19 
STOCK2S-
97295 
(CHEMBL-
1441606) 
~20 4.46 38.66 2 0 1 true Hit validation 
20 
STOCK2S-
12571 
~50 4.98 38.66 2 0 1 true Hit validation 
Table 5. Hit compounds derived from the 1,3-benzoxazi -4-one chemotype. 
Entry Structure IDNUMBER 
IC50 
C1s; 
µM 
LogP TPSA 
H bond 
acceptors 
H b nd 
donors 
Rotatable 
bonds 
Lipinski
rule of 5 
(4 of 4) 
Chemoinformatics 
21 Z55992821 0.241 3.20 38.66 2 0 1 true Pharmacophore 
22 Z55992803 3.6 2.35 51.80 2 0 1 true Hit validation 
23 Z55992807 41 2.26 51.80 2 0 1 true Hit validation 
2.4.2. Factor Xa Inhibition 
Out of the 20 C1s it compounds 6 compounds exhibited significant selectivities towards C1s 
(Table 6., remaining activities are > 85% in the Factor Xa assay). 
Table 6. Factor Xa inhibition of the 20 C1s inhibitor hit compounds. (Compounds with remaining 
activities >80 % are shown in bold). 
Entry Factor Xa 10µM Remaining Activity % Entry Factor Xa 10µM Remaining Activity % 
1 30 3 1 26.02 
2 3.1 2 5 4
3 4.93 3 98 6
4 86 2 4 61.4 
5 48 5 82 
6 3 6 77.6 
7 92 1 7 100 
8 76.5 18 46 1
9 2.39 1 53.6
10 78.1 22 0.14 
Z55992807 41 2.26 51.80 2 0 1 true Hit validation
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2.4.2. Factor Xa Inhibition
Out of the 20 C1s hit compounds 6 compounds exhibited significant selectivities towards C1s
(Table 6, remaining activities are > 85% in the Factor Xa assay).
Table 6. Factor Xa inhibition of the 20 C1s inhibitor hit compounds. (Compounds with remaining
activities >80 % are shown in bold).
Entry Factor Xa 10 µM Remaining Activity % Entry Factor Xa 10 µM Remaining Activity %
1 30.3 11 26.02
2 43.1 12 85.4
3 4.93 13 98.6
4 86.2 14 61.4
5 48.3 15 82
6 92.3 16 77.6
7 92.1 17 100
8 76.5 18 46.1
9 2.39 21 53.6
10 78.1 22 0.14
3. Discussion
In our drug discovery project, the first attempt was to generate a C1s inhibitor-focused
library applying 2D similarity searches on multimillion compound commercial libraries based
on the structure of known inhibitors collected from PubChem and literature sources. Many C1s
inhibitors contain amidine (or guanidine) moieties binding to Asp611 [5]. However, compounds with
such functionalities are rarely available from commercial vendor libraries, therefore, we turned to
the generation of their bioisosteric replacements and other recently published inhibitors that lack
such structural units. The PubChem and literature seed compounds (12) are composed of four
chemotypes: 1,2,3-benzotriazoles (4), 1,2,4-triazoles (4), imidazoles (3), and 3,1-benzoxazin-4-ones (1).
The performance of the 2D similarity search relies on the diversity of the seeds and the searchable
chemical space (vendor libraries), the computational methods (fingerprints) as well as the applied
criteria (similarity cut-off values, and property space filters etc.). Various research groups have
analyzed large activity data sets and come to the conclusion that on average there is a 30%
probability that two compounds shared the same activity within a certain similarity cut-off
(Tanimoto coefficient ≥ 0.85) [37–39]. However, applying T ≥ 0.65 cut-off value the virtual hits
still represent high level of acceptable similarities. On the other hand, such structural similarity does
not necessarily lead to novel chemotypes or scaffolds, which is one of the major challenges of the
contemporary drug discovery [40].
One of the critical issues in 2D ligand-based similarity selection approaches is the novelty vs.
similarity [41], thus, structural analysis of the hits is a necessary task after biological evaluation
of the focused library. Novelty could mean different core structure (scaffold/chemotype) or in the
case of linear compounds a different arrangement of the various motifs although in a different
substitution pattern [42]. After diversity selection and visual inspection, we purchased 50 compounds,
which contained 1,2,3-benzotriazoles (16), 1,2,4-triazoles (15), imidazoles (6), 3,1-benzoxazin-4-ones
(5) and five unrelated (novel) chemotypes (see Supplementary Materials, Tables S2–S4) at T ≥ 0.65
Tanimoto similarity level. We did not go under this threshold, which might have significantly reduced
the hit rate. Indeed, biological screening led to a relatively high hit rate: 22%, however, did not
reveal novel chemotypes. The distribution of the hits was 1,2,3-benzotriazoles (6), 1,2,4-triazoles (4),
imidazoles (only one weak hit), 3,1-benzoxazin-4-ones (1).
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The hit structures were closely related to the seed compounds but revealed new analogues
with different substituent pattern and improved C1s inhibitory activities. The two highest activity
compounds (#9 and #10) belonged to the 1,2,4-triazole cluster (IC50 = 12 and 44 nM).
In order to identify C1s inhibitors with novel chemotypes we turned to building 3D binding and
pharmacophore models. 3D modelling/pharmacophore. The docking studies with the unmodified
1ELV structures resulted in relatively low scores for the most active Subasinghe amidine compounds
(with Ki > 1 µM [5]) and very low scores for the non-amidine type (Chen [11] and 2D focused library
hit compounds) and especially low scores for the FUT-175, a high activity C1s inhibitor (IC50 = 29 nM)
published by Aoyama et al. [4] in 1984, and often used as a reference compound. The saltbridge
indicated by Subasinghe between Asp 611 and the protonated amidine groups were observable for
most of the poses but the other parts of the ligands were disposed. The scores for the non-amidine
compounds (Chen [11] and 2D focused library hits) were even lower. Our hypothesis was that the
orientation of the amino acid side chains in the binding site was not optimal for the binding, and that is
why we decided to improve the geometry of the site with induced fit docking (IFD) approach using the
most active Subasinghe thiopheneamidine inhibitor: compound 49 (Ki = 60 nM [5]). The re-docking of
compound 49 in [5] and the docking of the FUT-175 reference compound into the IFD improved 1ELV
structure resulted in significantly higher scores (−10.215 and −10.161) and better poses (Figure 1a–d).
These values corresponded to the biological activity values.
All 39 Subasinghe’s thiopheneamidine inhibitors [5] were successfully docked into the IFD 1ELV
structure resulted in a better alignment and significantly higher scores (between −7.5 and −10.5).
No strong correlation between the biological data and the docking scores could be observed, but the
inactive compounds were given lower scores while only a few active compounds were underscored
(see Supplementary Materials). The data indicated that the docking might be able to identify the C1s
active compounds in the course of an in silico screening.
As a next step our validation, a number of biologically active but chemically diverse C1s inhibitors
were also docked. The first group of compounds was identified as hits of the 2D similarity-based
focused while the other group of compounds was published by Chen et al. [11] as a result of a virtual
screening study. The Glide docking scores (empirical scores of binding affinity expressed in kcal/mol)
for both groups of non-amidine compounds were significantly lower than expected (between −5.0 and
−7.0). The second group also contained a number of inactive compounds (IC50 > 50 µM), these were
predicted scores comparable with those of the active ones (Tables 7 and 8).
These results indicate that our model might not be able to identify other than amidine inhibitors.
The gap between the biological data and the scores could be a result of the lack of our knowledge on
the C1s small molecule binding. We assumed these compounds were blocking the access of the protein
substrates toward the catalytic residues and we were focusing on the catalytic Ser617 as the obvious
location of the inhibitor binding. This seems to be reasonable in the case of the amidine compounds
considering that the distance between Asp611 and Ser617 is comparable with the size of these inhibitors.
However, while the dockings are indicating that the salt bridge with Asp611 could be a key factor in
the case of the Subasinghe compounds’ and FUT-175 binding, it was hard to find something equally
strong in case of the non-amidine compounds and it is quite possible that the binding mode of these
inhibitors are fundamentally different. It is also possible that they bind in another location further
away from Ser617, which we have not investigated, and they are blocking the enzyme with a different
mechanism. Thus, we do not know the exact location of the potential inhibitor binding site and the
mechanism of the inhibition and we have no coordinates of inactive enzyme to compare with our
results. Unfortunately, no docking study other than for the Subasinghe amidine inhibitors [5] has been
reported so far for the C1s enzyme. In conclusion, 3D model validation resulted in negative results
providing low docking scores and the models did not discriminate the active and non-active structures
for non-amidine inhibitors.
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Figure 1. Docking results with the optimized 1ELV structure. Best docking pose (a) and ligand 
interaction diagram (b) for compound FUT-175; and best docking pose (c) and ligand interaction 
diagram (d) for Subasinghe’s compound 49. Both inhibitors’ amidine group formed a salt bridge with 
Asp611 and a further H-bond with Ser612. In case of FUT-175 a second salt bridge was formed 
between the guanidine group and Glu463 and an additional H-bond with the catalytic Ser617 was 
also observed. Compound 49 was stabilized through its pyrazole ring forming both a π-π stacking 
interaction with Phe511 and a π-cation interaction with Lys 614. 
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based focused while the other group of compounds was published by Chen et al. [11] as a result of a 
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Figure 1. Docking results with the optimized 1ELV structure. Best docking pose (a) and ligand
interaction diagram (b) for compound FUT-175; and best docking pose (c) and ligand interaction
diagram (d) for Subasinghe’s compound 49. Both inhibitors’ amidine group formed a salt bridge with
Asp611 and a further H-bond with Ser612. In case of FUT-175 a second salt bridge was formed between
the guanidine group and Glu463 and an additional H-bond with the catalytic Ser617 was also observed.
Compound 49 was stabilized through its py zole ring forming both a pi-pi stacking interaction with
Phe511 and a pi-cation interaction with Lys 614.
Table 7. Biological data, docking scor s and emodel scores of the non-amidin C1s inhibitors obtained
by the 2D simi r ty search.
Entry IC50 (µM) Glide Docking Score Glide Emodel Score
1 0.083 −6.404 −58.321
2 0.091 −6.866 −65.171
4 1.300 −7.003 −60.058
5 1.850 −6.791 −59.201
7 3.870 −7.558 −65.852
9 0.012 −6.592 −62.262
10 0.044 −6.099 −54.519
11 0.094 −6.993 −60.231
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Table 8. Biological data, docking scores and emodel scores of selected non-amidine literature inhibitors
(Chen et al., [11]).
Compound ID IC50 (µM) Glide Docking Score Glide Emodel Scores
17178137 11.0 −5.538 −53.585
4951143 19.1 −5.595 −57.808
2986934 0.34 −6.892 −67.866
710644 1.09 −6.556 −55.670
5146207 >50 −6.495 −54.781
807111 >50 −5.909 −58.543
1107361 >50 −6.621 −67.010
827004 3.04 −7.022 −55.173
4957387 32.9 −6.737 −60.524
898930 5.54 −6.733 −57.680
These uncertainties prompted us to use a different approach instead of docking in the virtual
screening, and this is why we turned to a pharmacophore-based method. Recent studies on
pharmacophore based drug discovery in silico studies were reported where ligand- and structure
based approaches were successfully applied [43–45]. The number of published human C1s inhibitory
data in the literature is very limited as well as the suitable target structures, therefore we were focusing
a purely ligand based method. The largest group was the above mentioned amidine compounds
investigated by Subasinghe et al. [5–7]. For practical reasons we were focusing on different kind
of compounds.
After a comprehensive database survey three sources with large number of non-amidine active
compounds were identified. The first source of data was a journal (Biomolecules) article published by
Chen et al. [11]. The authors tested 17 compounds and nine of them were found to be active, including
1,2,3-benzotriazoles (5) and phenylfuran esters (4). The second group of active compounds were
found in an unpublished bioassay AID 538 and 787 [9,10] from the PubChem database [46]. A total
number of 184 compounds were tested, 23 of them proved to be active including 1,2,4-triazoles (6),
1,2,3-benzotriazoles (5), imidazoles (4), 3,1-benzoxazin-4-ones (2) and other structures (6). The third set
of compounds was the collection based on our 2D in silico selection from various commercial sources
(see above). Twelve out of the 50 tested compounds were active, including 1,2,3-benzotriazoles (6),
1,2,4-triazoles (4), 3,1-benzoxazin-4-ones (2) and an imidazole.
Based on common scaffolds, these data were merged into three sets of structurally related
compounds, a 1,2,3-benzotriazole set with 16 active compounds, a 1,2,4-triazole set with 10 active
compounds and a 3,1-benzoxazin-4-one set with four active compounds (Scheme 4). The imidazole
compounds were structurally diverse so it was impossible to build a fourth set for consensus
pharmacophore modelling. The inactive compounds were used as a ‘decoy’ set in the pharmacophore
validation during the process.
The Top5 hypotheses of each set was tested during the final validation with the Hypothesis
Validation task of Schrödinger’s Phase module using the Enrichment Viewer Panel involving the above
mentioned inactive decoy set. Receiver Operator Characteristic (ROC) area under the curve diagrams
were generated based on the false positive and true positive rates of the modes and BEDROC160.9 scores
(a modified BEDROCK score recommended for hypothesis selection) enrichment factor for recovering
1% of the known actives (EF1%) scores were also calculated together with the ROC scores. Hypothesis
with the best scores were selected as final models of the three (1,2,3-benzotriazole, 1,2,4-triazole and
3,1-benzoxazin-4-one) sets and utilized in the screenings (Figures 2–4 and Tables 9–11).
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Score 
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score 
EF1% 
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Pharmacophore 
Model 
PhaseHypoScore 
Survival 
Score 
Selectivity 
Score 
BEDROC160.9 
(from validation) 
ROC EF1% 
AAARR_1 1.288 4.808 1.373 0.86 0.62 5.56 
ARRR_1 1.279 4.646 1.214 0.86 0.52 5.56 
i r . The s lected 3,1-benzoxazin-4-one model (AARR_3). Unlik the other two models,
this structure is planar, the two accepto groups (A1 and A3) are located more close to each ot r il
i l f t f c t er.
Common models in luding all four types of compounds (1,2,3-benzotriazoles, 1,2,4-triazoles,
3,1-benzoxazin-4-ones and imidaz les – 50 compounds altogether) has been also developed
(see Supplementary Information). Only one of these model had a full match for all the active
compounds (13) while the other two common hypotheses (ARRR_1 and AARR_1) had only 10 out
of the 13 activ compounds fully matched. The best common model (with all active compounds
matching) was not fundamentally different from the AARR_3 (3,1-benzoxazin-4-one) model but it’s
survival- and BEDROC scores however were significantly lower (see Supplementary Information) and
therefore we have decided not to use them in our virtual screening campaign.
The pharmacophore based screening resulted in six active compounds out of the purchased 21
(hit rate = 28.5%). Such library contained 1,2,3-benzotriazoles (2); imidazoles (2), 3,1-benzoxazin-4-ones
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(5) as known chemotypes, while 12 compounds belonged to previously not identified chemotypes
among the C1s inhibitors. Out of the novel scaffold-bearing compounds two compounds showed
inhibition against C1s: One compound had a thieno[2,3-d][1,3]oxazin-4-one core (#17; 549 nM) and
another belonged to 1,3-benzoxazin-4-ones (#21; 241 nM), which can be considered as a bioisoster
of the known “reverse” 3,1-benzoxazin-4-one chemotype. The remaining active compounds were
3,1-benzoxazin-4-ones (2) and benzotriazoles (2).
Table 9. Top 5 pharmacophore hypotheses for the 1,2,3-benzotriazole set. A–acceptor group;
H–hydrophobic group; R–aromatic group.
Pharmacophore
Model PhaseHypo-Score
Survival
Score
Selectivity
Score
BEDROC160.9
(from Validation) ROC EF1%
ARRR_1 1.319 5.317 1.219 0.67 0.63 2.78
ARRR_2 1.318 5.305 1.211 0.74 0.51 2.78
AARR_1 1.315 5.247 1.150 0.67 0.79 2.78
AARR_2 1.314 5.236 1.139 0.67 0.80 2.78
AARR_3 * 1.314 5.231 1.141 0.92 0.81 5.56
* Hypothesis selected as best 1,2,3-benzotriazole model.
Table 10. Top 5 pharmacophore hypotheses for the 1,2,4-triazole set. A–acceptor group; H–hydrophobic
group; R–aromatic group.
Pharmacophore
Model PhaseHypoScore
Survival
Score
Selectivity
Score
BEDROC160.9
(from Validation)
ROC
Score EF1%
AHRR_1 * 1.283 5.175 1.358 0.52 0.40 2.78
AAAHRR_1 1.259 5.833 2.034 0.29 0.09 2.78
AAAHRR_2 1.258 5.828 2.026 0.14 0.11 0.00
AAAHRR_3 1.258 5.826 2.029 0.11 0.11 0.00
AHRRR_1 1.249 5.665 1.87 0.04 0.23 0.00
* hypothesis selected as best 1,2,4-triazole model.
Table 11. Top 5 pharmacophore hypotheses for the 3,1-benzoxazin-4-one set. A–acceptor group;
R–aromatic group.
Pharmacophore
Model PhaseHypoScore
Survival
Score
Selectivity
Score
BEDROC160.9
(from Validation) ROC EF1%
AAARR_1 1.288 4.808 1.373 0.86 0.62 5.56
ARRR_1 1.279 4.646 1.214 0.86 0.52 5.56
AARR_1 1.274 4.574 1.142 0.86 0.76 5.56
AARR_2 1.274 4.562 1.131 0.86 0.66 5.56
AARR_3 * 1.273 4.550 1.118 0.86 0.84 5.56
* hypothesis selected as best 3,1-benzoxazin-4-one model.
Since only one compound represented each new chemotypes (they were “singletons”) the outcome
of the pharmacophore based in silico screening required an extended hit validation. Applying a
comprehensive substructure search on the two novel scaffold structures we selected 19 analogues
around the thieno[2,3-d][1,3]oxazin-4-one core with diverse substitution pattern (close and remore
analogues) and we purchased 11 compounds. Similarly, we selected seven analogues around the
1,3-benzoxazin-4-one core and purchased five analogues. As a control we also purchased two
compounds with chromen-4-one structures in which N-3 was replaced with a carbon. Hit validation
set resulted in three active analogues for the thieno[2,3-d][1,3]oxazin-4-one core (best: #18; 845 nM);
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and two active residues for the 1,3-benzoxazin-4-one chemotype (best: #22; 3.6 µM), which validated
the obtained new chemotypes. The hit rate of the combined hit (defined as an activity ≤ 10 µM)
validation set was 13% (excluding the unrelated chromen-4-one structures).
In the three screening rounds we tested altogether 89 compounds. We also analyzed the hit
rates according to the chemotypes. For the known chemotypes we found: 1,2,3-benzotriazoles: 44%;
1,2,4-triazoles: 26.6%; 3,1-benzoxazin-4-ones: 30% hit rate. For the novel chemotypes we obtained
1,3-benzoxazin-4-one: 33.3%; thieno[2,3-d][1,3]oxazin-4-one: 16.6%, which proves that the hit validation
of these novel scaffolds was successful.
3.1. Structure–Activity Relationship of the Chemotypes
3.1.1. 1,2,3-Benzotriazoles
The highest number of activity data are available for this chemotype. Recently, Chen et al. [11]
attempted a preliminary SAR based on the available PubChem activity data and their in-house activity
measurements. We extended the list with eight active and 10 inactive compounds, thus, altogether
20 active compounds and numerous inactive compounds refined the SAR determination (Scheme 5).
The additional data confirmed mostly the previous findings reported by Chen [11]. The major
facts are the following:
(1) A substituted benzoyl group in the N-1 position is required for the activity. Unsubstituted benzoyl
groups or replacement with an N-1 furoyl group is detrimental to the activity.
(2) The position and nature of the functional groups on the benzoyl group have a significant impact
on the activity. The para position is much favored, followed by the ortho position. Substituents
in the meta position generally diminish or occasionally fully eliminate the activity. However,
meta/para disubstitution somewhat counterbalances this negative effect.
(3) Electron donating groups (amide, ether, thioether) at the para position are particularly beneficial.
Alkyl groups are weaker in the para position, but interestingly bulky alkyl groups (t-butyl) look
better. Interestingly, while a meta/para difluoro-substituted compound is relatively good inhibitor,
analogous dichloro substitution and para-bromo substitution led to inactive compounds. Electron
acceptor groups in the para position (such as nitro group) eliminate the activity.
Molecules 2019, 24, 3641 16 of 28 
 
(2)  The position and nature of the functional groups on the benzoyl group have a significant 
impact on the activity. The para position is much favored, followed by the ortho position. 
Substituents in the meta position generally diminish or occasionally fully eliminate the 
activity. However, meta/para disubstitution somewhat counterbalances this negative effect. 
(3)  Electron donating groups (amide, ether, thioether) at the para position are particularly 
beneficial. Alkyl groups are weaker in the para position, but interestingly bulky alkyl groups 
(t-butyl) look better. Interestingly, while a meta/para difluoro-substituted compound is 
relatively good inhibitor, analogous dichloro substitution and para-bromo substitution led 
to inactive compounds. Electron acceptor groups in the para position (such as nitro group) 
eliminate the activity. 
From our focused library screeni g we had s me interesting obse vations regarding the effect 
of bulk substituents in the para and ortho positions. The hydrophobic biphenyl group is relatively 
good, while the benzoyl bridged bis(benzotriazole) compound (1-[4-(1,2,3-benzotriazole-1-
carbonyl)benzoyl]-1,2,3-benzotriazole) becomes inactive. Similarly, the ortho-methoxy substituted 
benzoyl is active, while the bulky phenyl ether loses the activity. We also found that changing the 
benzoyl group to benzyl eliminates the activity. Only one compound (5) was found in the ChEMBL 
biological activity database ((https://www.ebi.ac.uk/chembl) but with unrelated biological activities 
(FXI, FXII inhibition). 
 
Scheme 5. Examples of the 1,2,3-benzotriazoles structure–activity relationship. 
3.1.2. 1,2,4-Triazoles 
There are only few known active C1s inhibitors of this chemotype. The data are available from 
the PubChem. We tested 15 analogues and found four active compounds, which were among the 
highest activity compounds. (#9: IC50= 12 nM; #10: IC50 = 44 nM; #11: IC50 = 94 nM). These compounds 
derived from the 2D similarity search. The measured compounds represented a well-defined 
chemical space, and thus allowed us to draw some conclusions about the SAR (Scheme 6): 
(1)  Unsubstituted aroyl (furan-carbonyl, thiophene-carbonyl and benzoyl) groups in the N-1 
position are beneficial. Ortho and para substitutions of the N-1 benzoyl group (such as 
methyl, methoxy, and fluoro) have also positive contributions. Replacing the N-1 aroyl 
groups to propionyl, benzyl-carbonyl leads to the loss of the activity. 
(2)  Replacing the methyl-thio group to primary/secondary amines or bulky aralkyl groups 
results in inactive compounds. 
(3)  Changing the C-3 furyl group to thiophenyl (PubChem, CID 4257399; IC50 = 880 nM) or 3-
pyridyl group (#12; IC50 = 2.4 μM) retains the activity, while replacing with para-chloro-
phenyl leads to inactivation. 
Two hit compounds (9, 11) were found in the ChEMBL biological activity database but with 
various unrelated biological activities (thrombin, FXI, FXII inhibition). 
Sch me 5. Examples of the 1,2,3-benz tri les structure–activity relationship.
From our focused library screening we had some interesting observations regarding
the effect of bulk substituents in the para and ortho positions. The hydrophobic
biphenyl group is relatively good, wh le the benzoyl bridged bis(benzotriazole) compound
(1-[4-(1,2,3-benzotriazole-1-carbonyl)benzoyl]-1,2,3-benzotriazole) becomes inactive. Similarly,
the ortho-methoxy substituted benzoyl is active, while the bulky phenyl ether loses the activity.
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We also found that changing the benzoyl group to benzyl eliminates the activity. Only one compound
(5) was found in the ChEMBL biological activity database ((https://www.ebi.ac.uk/chembl) but with
unrelated biological activities (FXI, FXII inhibition).
3.1.2. 1,2,4-Triazoles
There are only few known active C1s inhibitors of this chemotype. The data are available from the
PubChem. We tested 15 analogues and found four active compounds, which were among the highest
activity compounds. (#9: IC50= 12 nM; #10: IC50 = 44 nM; #11: IC50 = 94 nM). These compounds
derived from the 2D similarity search. The measured compounds represented a well-defined chemical
space, and thus allowed us to draw some conclusions about the SAR (Scheme 6):
(1) Unsubstituted aroyl (furan-carbonyl, thiophene-carbonyl and benzoyl) groups in the N-1 position
are beneficial. Ortho and para substitutions of the N-1 benzoyl group (such as methyl, methoxy,
and fluoro) have also positive contributions. Replacing the N-1 aroyl groups to propionyl,
benzyl-carbonyl leads to the loss of the activity.
(2) Replacing the methyl-thio group to primary/secondary amines or bulky aralkyl groups results in
inactive compounds.
(3) Changing the C-3 furyl group to thiophenyl (PubChem, CID 4257399; IC50 = 880 nM) or 3-pyridyl
group (#12; IC50 = 2.4 µM) retains the activity, while replacing with para-chloro-phenyl leads
to inactivation.
Two hit compounds (9, 11) were found in the ChEMBL biological activity database but with
various unrelated biological activities (thrombin, FXI, FXII inhibition).Molecules 2019, 24, 3641 17 of 28 
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3.1.3. 3,1-Benzoxazin-4-ones
This chemotype (2-aryl-3,1-benzoxazin-4-ones) was originally reported by Gilmore and
co-workers in 1996. The best compound was 2-(2′-iodophenyl)-3,1-benzoxazin-4-one (CID296008,
IC50= 1.25 µM) [47]. Later the previously cited HTS campaign identified two further hit compounds [11],
and one of them was applied as a lead compound (seed #10; see Supplementary Materials) in the 2D
similarity search. Ten compounds were tested and four were found active (three compounds had
inhibitory activity below 10 µM). The following limited SAR observations were made (Scheme 7):
(1) Halogen (chloro) in the C-7 position is much favored over the C-6 position as well as to the
unsubstituted 2-aryl-3,1-benzoxazin-4-ones.
(2) Replacing the furyl group to 2′-iodo-phenyl at the C-2 position improves the activity,
while 4′-fluorophenyl group in the same position eliminates the activity.
(3) If the furyl group at the C-2 position replaced with a bulky 2-benzofuryl group the compound
loses the activity.
Molecules 2019, 24, 3641 18 of 28 
 
 
Scheme 7. Examples of the 3,1-benzoxazin-4-ones structure – activity relationship. 
3.1.4. 1,3-Benzoxazin-4-ones 
Altogether six compounds were tested and three were found active (two compounds had 
inhibitory activities below 10 μM). This novel chemotype is closely related to the previous one, the N 
and O changed positions (N: 1 to 3; O: 3 to 1), thus, the two structures can be considered as 
bioisosteres. This close relationship suggests that the main SAR characteristics should be very similar 
(Scheme 8). Indeed, we found a very similar behavior to the 3,1-benzoxazin-4-one chemotype. The 
biological activities of this “reverse” benzoxazine chemotype are comparable but slightly better (ca. 
two fold): 
(1)  Since thiophene and furan are interchangeable in many bioactive compounds, therefore, the 
trend of the decreasing activity between #21 and #22 is comparable to the same direction 
between #13 and #15, thus, halogen (chloro) in the C-7 position is much favored over the C-
6 position. 
(2)  Introducing 4′-chlorophenyl group or alkyl groups at the C-2 position instead of furyl or 
thiophenyl groups leads to inactivation. 
(3)  Finally, if N-3 is replaced with carbon forming the corresponding chromen-4-one, it results 
in a complete loss of the activity. 
None of the hit compounds was found in the ChEMBL biological activity database. 
 
Scheme 8. Examples of the 1,3-benzoxazin-4-ones structure–activity relationship. 
. xa les f t e , - i - - t
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3.1.4. 1,3-Benzoxazin-4-ones
Altogether six compounds were tested and three were found active (two compounds had inhibitory
activities below 10 µM). This novel chemotype is closely related to the previous one, the N and O
changed positions (N: 1 to 3; O: 3 to 1), thus, the two structures can be considered as bioisosteres.
This close relationship suggests that the main SAR characteristics should be very similar (Scheme 8).
Indeed, we found a very similar behavior to the 3,1-benzoxazin-4-one chemotype. The biological
activities of this “reverse” benzoxazine chemotype are comparable but slightly better (ca. two fold):
(1) Since thiophene and furan are interchangeable in many bioactive compounds, therefore, the trend
of the decreasing activity between #21 and #22 is comparable to the same direction between #13
and #15, thus, halogen (chloro) in the C-7 position is much favored over the C-6 position.
(2) Introducing 4′-chlorophenyl group or alkyl groups at the C-2 position instead of furyl or thiophenyl
groups leads to inactivation.
(3) Finally, if N-3 is replaced with carbon f rming the corresponding chromen-4-one, it results in a
complete loss of the activity.
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None of the hit compounds was found in the ChEMBL biological activity database.
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None of the hit compounds was found in the ChEMBL biological activity database.
3.1.5. Thieno[2,3-d][1,3]oxazin-4-ones
Altogether 12 compounds were tested and four were found active (two compounds had inhibitory
activities below 10 µM). This novel chemotype is also related to the known 3,1-benzoxazin-4-one cores;
the fused phenyl group was replaced with thiophene, thus, it is expected that the SAR characteristics
should reveal some similarities (Scheme 9):
(1) Similarly to 3,1-benzoxazin-4-ones replacing the furyl group with 2′-halogeno (bromo)-phenyl
at the C-2 position retains the activity, while unsubstituted phenyl, 4′-tolyl, 4′-halogeno
(fluoro, chloro) substituted phenyl groups in the same position significantly reduce or completely
eliminate the activity.
(2) Introducing a bulky (thiophenyl) group into the thiophenyl part of the fused ring leads to
complete inactivation.
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The hit compound 17 was previously measured for C1s inhibitory activity as reported in the
ChEMBL and PubChem (https://pubchem.ncbi.nlm.nih.gov/) but it was claimed to be “inactive” due
to inadequate data processing [9]. Another hit compound (18) was found in the ChEMBL biological
activity database but with unrelated biological activities (FXI, FXII inhibition).
3.1.6. Structural Features of the C1s Selectivity over Factor Xa
Looking at the Factor Xa inhibition of the 20 C1s inhibitor hit compounds we identified the
following structural features: Bulk substituents in the para position of the phenyl group, which is
either isolated (such as in 1,2,3-benzotriazoles and 1,2,4-triazoles) or part of the rings (such as
3,1-benzoxazin-4-one; or thieno[2,3-d][1,3]oxazin-4-ones) favors the selectivity over Factor Xa (#4, #6,
#7, #13). On the other hand, if substituents are in the ortho (or occasionally in meta) positions the
selectivity is reduced (#3, #9, #22).
4. Materials and Methods
4.1. Molecular Biology. Protein Expression of C1s
Recombinant C1s and C1r fragments (CCP1-CCP2-SP, the γB catalytic region) containing the
serine protease domain were expressed in E. Coli BL21(DE3)pLysS host strain (transformed with
pET-17b vector) in form of inclusion bodies; proteins were isolated, renatured and purified as published
earlier [48]. Recombinant C1s, isolated in intact proenzyme form, was activated by limited proteolysis
using the recombinant, autoactivated C1r fragment. Activated C1s and C1r were separated using Q
Sepharose HP (Amersham Biosciences, Little Chalfont, UK) anion exchange chromatography.
4.2. Assay Development
Two end-point assays have been developed for C1s inhibition assays: For screening assays a
specific, fluorescent amide substrate Boc-Leu-Gly-Arg-AMC (Sigma, St. Louis, MO, USA), representing
the cleavage site sequence of C2 was used with relatively high enzyme concentration (0.2 µM).
Assay conditions: 20 mM HEPES (pH 7.4), 200 mM NaCl, 0.05% Tween20, 1% DMSO; 384 microplate
format; 10 µL enzyme + 10 µL inhibitor compounds (final concentration: 10 µM); incubation time
and temperature: 10 min, RT; then 20 µL substrate solution was added (1 mM final concentration);
incubated (45 min, 30 ◦C) and the fluorescence have been read (355/460 nm; Wallac 1420 Victor2
microplate reader, Perkin Elmer, Waltham, MA, USA). FUT175 (Sigma), a non-specific, highly active
serine protease inhibitor has been used for inhibition control.
IC50 measurements have been carried out with high concentration of a sensitive thioester substrate
(Z-Lys-SBzl, Sigma) combined with DTNB thiol reagent (Sigma) and low enzyme concentration
(below 1 nM), in the same buffer used for 10 µM screening, in a 96 well microplate format (in 100 µL),
using non-binding plates (Greiner, Kremsmünster, Austria). 40µL enzyme + 10µL inhibitor compounds
were incubated (10 min, RT), and 50 µL substrate solution (1 mM final concentration) was added;
incubated for 45 min and finally absorbance was read (405 nm) with a Perkin Elmer Wallac 1420 Victor2
microplate reader. The assay has been validated with FUT175 with IC50 = 2 × 10−9 M (in contrast with
the reported values: 2,9 × 10−8 M [4] and 3.2 × 10−7 M [49]); revealing high sensitivity of the assay
developed for IC50 measurements.
4.3. Factor Xa (FXa) Assay Development
FXa activity assay has been developed to test specificity of the selected inhibitors. 10 µM one-point
screen and IC50 measurement have been carried out as follows:
Human isolated Factor Xa protein was purchased from ThermoFisher Scientific
(Waltham, MA, USA). An end-point assay was carried out using the fluorescent amide substrate
Boc-Leu-Gly-Arg-AMC used for C1s 10 µM screen; assay conditions: 20 mM HEPES (pH 7,8) 100 mM
NaCl, 10 mM CaCl2 30 ◦C, 0.05% TWEEN-20, 1% DMSO; low enzyme concentration (about 1 nM);
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in a 96 well microplate format (in 100 µL), using non-binding black plates (Greiner). 40 µL enzyme +
10 µL inhibitor compounds were incubated (10 min, RT), and 50 µL substrate solution (500 µM final
concentration) was added; incubated for 30 min and finally the fluorescence has been read. Edoxaban
(Cayman Chemical, MI, USA), a specific and highly potent FXa inhibitor has been used for inhibition
control and for validation of the assay with a measured IC50 = 0.649 nM value, according to the
published data (Ki of 0.561 nM [50]).
4.4. Chemoinformatics Methods
4.4.1. 2D Similarity Selection
One of the key concepts in the ligand-based vs. approaches [51,52] is the Similarity Property
Principle, which states that similar molecules should have similar biological properties [53,54]. In other
words, a molecule that has not been tested for biological activity but that is structurally similar to
an active molecule (reference or seed molecule) is also likely to be active [38]. If determining the
similarity between biologically active reference compound and each molecule in a database, followed
by ranking the database molecules according to the similarities would lead to potentially active,
target-focused libraries.
Similarity search uses 2D fingerprints, i.e., binary strings encoding the presence or absence of
a substructure within the molecules [55]. Applying simple 2D fingerprints is often the method of
choice [56] particularly when numerous active, reference compounds and multimillion compound
databases are available. Its computational efficiency is coupled with demonstrated effectiveness in
many comparative studies [57].
Rapid 2D similarity search can be performed on multimillion compound’s databases if structures
of active molecules are available therefore, it is a “real time” method compared with the other
ligand-based approaches.
Focused library screening often results in a many fold increase in the hit rate compared with
random screening of a commercial libraries [14,15]. In many cases virtual screening methods and
in vitro HTS were combined [58] and found complementary to each other [40,59,60].
The 2D similarity search can often be refined using physicochemical descriptors in property–based
virtual screening.
If most of the parameters of the drug candidate fall into the pre-defined ranges the concerning
molecule could be administered orally [61]. The major physico-chemical properties (Mwt, LogP,
H-bond donors/acceptors, rotatable bonds and topological polar surface area – tPsa) were determined
by the Calculation Suit of InstJChem (ChemAxon Ltd., Budapest, Hungary). The first four parameters
are included in the Lipinski’s Rule of 5 [62], while the other two are referred to as the Veber rules [63].
We applied InstJChem software (Version: 16.12.12.0, date: 12.15.2016) for 2D similarity search.
InstJChem uses the Chemical Hashed Fingerprints for the 2D similarity search (as discussed earlier).
Normally, in the initial similarity search phase a compound was defined as similar, if the Tanimoto
coefficient was > 0.65 compared to any reference compound. In the following screening rounds
(e.g., in hit validation or hit refinement), we often applied higher Tanimoto similarity cut-off values.
Most frequently Tanimoto coefficient [64] is used for measuring similarity [53,65] in spite of its marked
size-dependency [66]. It typically yields low similarity values when the reference molecules are
relatively small and just lead to few bits set in the fingerprint.
The searchable drug-like chemical space, which is the major target of the similarity search,
was composed by existing compounds: non-exclusive commercial libraries were available from the
actual edition of the top vendor databases (~5 million compounds): Asinex, ChemBridge, ChemDiv,
Enamine, Interbioscreen, Life Chemicals, Specs, UkrOrg, etc. [21–28]. The biologically active chemical
space is composed of known, biologically active reference (seed) compounds. Known C1s inhibitors
were collected from the available literature, PubChem and various commercial databases.
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4.4.2. 3D Modelling
X-Ray Structures
In the past two decades, ten X-ray crystallographic structures of human C1s have been published
in the literature with various (Table 12) resolutions [29,67–71]. Seven of these structures have not
included the catalytic serine protease domain and therefore they were unsuitable for structure-based
inhibitor modelling, but the remaining three structures were also problematic mostly because the lack
of co-crystalized small molecule inhibitors.
Table 12. Published protein C1s X-ray crystallography structures and their domain coverage.
Domains Position Length (aa)
X-Ray Structures
1ELV * 1NZI 4J1Y * 4LMF 4LOR 4LOS 4LOT 6F1C 6F1H 5UBM *
signal peptide 1–15 15 x x x x x x x x x x
CUB 1 16–130 115 − + − + + − − + + −
EGF-like 131–172 42 − + − + + − − + + −
CUB 2 175–290 116 − − − + + + + + + −
Sushi/CCP1 292–356 65 − − + − - + + − − +
Sushi/CCP2 357–423 67 + − + − − - + − − +
SP (peptidase) 438–688 243 + − + − − − − − − +
* Structures may be suitable for modelling.
The first human C1s structure has been an apo form of the enzyme published by Gaboriaud et al.
in 2000 (PDB code 1ELV) with 1.7 Å resolution contained the substrate binding site [29]. This structure
seemed to be an obvious choice as it has been used for docking studies by the research group of
Subasinghe and Travis [5–7].
The second structure that could be considered has been reported by Perry et al. in 2013 (PDB code
4J1Y) as the zymogen form of the enzyme co crystalized with its endogenous substrate, complement
C4 with a poor 2.66 Å resolution [69].
The third structure has been recently introduced by Pang et al. in 2017 (PDB code 5UBM), in which
the enzyme in complex with the protein inhibitor gigastasin (isolated from from the Giant Amazon
Leech, Haementeria ghilianii) with a medium resolution of 2.5 Å [70].
Ligand Preparation
Small molecule structures were downloaded from ChEMBL open bioactivity database
(https://www.ebi.ac.uk/chembl) in SMILES format [72], and converted into 2D structures via the JChem
for Excel application (JChem for Office (Excel) 2019.6.0.447, ChemAxon (http://www.chemaxon.com).
Ligand preparation was completed with Schrödinger’s LigPrepmodule (Schrödinger Release 2018-2:
LigPrep, Schrödinger, LLC, New York, NY, USA, 2018), structures were optimized with OPLS3e force
field (Schrödinger LLC, Release 2018-2, OPLS3e, 2018) [73], Epik module was used to the generation
of various stereochemistry (if undefined) as well as protonation- and tautomeric forms at pH = 7.4
(Schrödinger LLC, Release 2018-2: Epik, 2018) [74].
Protein Preparation and Docking
Protein structures were downloaded from the RCSB Protein Data Bank (https://RCSB.org) [75],
readied for docking by Schrödinger’s P Protein Preparation Wizard, standard settings were used
(Schrödinger Release 2018-2: Protein Preparation Wizard, 2018) [76]. Docking studies were completed
with Schrödinger’s Glide docking software (Schrödinger Release 2018-2: Glide, 2018) [77–79].
The doxing box was centered on the catalytic serine (Ser617) and the size of the box was set to
30 × 30 × 30 Å.
Docking studies were completed on both standard precision (SP) extra precision (XP) level with
standard settings, no constraints were used. In order to improve the improve the interactions between
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the binding site residues and the ligands, Induced Fit Docking (IFD) technics were applied on the 1ELV
in complex with published active C1s serine protease inhibitors (Schrödinger Release 2018-2: Glide
and Prime modules, Schrödinger LLC, 2018) [80]. An H-bond constrain has been applied between the
ligand’s amidine groups and the aspartic acid (Asp611) of the binding site thought to be essential in
substrate- and inhibitor binding. The optimized IFD complex – after the removal of the constrained
ligand – has been used for further docking studies.
4.4.3. Pharmacophore Modeling
The ‘create pharmacophore model with multiple ligands’ option of Schrödinger’s Phase
software was used for model building (Release 2018-2: Phase, Schrödinger LLC2018) [81]. After a
conformer library generation, a low energy conformer of an active ligand of the set was chosen as
reference and its variants of pharmacophore group were aligned with those of the other compounds’
pharmacophore features. Hypotheses were generated using the find best alignment and common
features pharmacophore method based on 4 to 6 features with 0.50 difference criterion cutoff and a
maximum of 2.0 Å distance tolerance for each features, at least 75% of active ligands should have
match. These model hypotheses than were scored and ranked by PhaseHypoScore, an optimized
weighted sum of Survival and (Boltzmann-enhanced Discrimination Receiver Operator Characteristic
area under the curve (BEDROC) score [82].
5. Conclusions
The CS is associated with various diseases such inflammation or auto-immune diseases.
Complement system-targeted drugs could provide novel therapeutic interventions against the above
diseases. C1s is an attractive target since it blocks the system at an early stage of the complement cascade.
Designing C1s inhibitors is particularly challenging since the inhibitors form a very distinct, narrow
bioactive chemical space as well as achieving selectivity over the other serine proteases. The typical
architecture of a small molecule inhibitor of C1s contains a heterocyclic amidine (or guanidine),
however, discovery of non-amidine inhibitors might have high value particularly if identifying novel
chemotypes and/or achieving improved selectivity.
For biological screening the C1s protein was expressed, two inhibition assays (fluorescent and
photometric) were developed and validated. The focused libraries were screened first at 10 µM
concentration and the IC50 values were determined for the most active compounds.
We attempted to apply various virtual screening approaches to identify C1s focused libraries
that lack the amidine/guanidine functionalities, then the libraries were evaluated by in vitro biological
assays. While 3D structure-based methods were not suitable for virtual screening, and 2D similarity
search did not lead to novel chemotypes, pharmacophore model generation allowed us to identify
two novel chemotypes with submicromolar activities. In three screening rounds we tested altogether
89 compounds and identified 20 hit compounds (<10 µM activities; overall hit rate: 22.5%). The highest
activity compound was 12 nM (1,2,4-triazole), while for the newly identified chemotypes 241 nM and
549 nM, respectively. For selectivity measurements the hit compounds were screened for Factor Xa
inhibition, and six compounds showed excellent selectivity. Further investigation of the compounds in
the complement system is under progress.
Supplementary Materials: The following are available online, Figure S1. Selected concentration dependency
curves (for C1s, Factor Xa); Figure S2. The common pharmacophore models; Table S1a. Seed compounds for 2D
similarity search (amidines and guanidines); Table S1b. Seed compounds for 2D similarity search (non-amidines
and non-guanidines); Table S2. Biological results of all purchased compounds (2D selection) (only the active
compounds are numbered); Table S3. Biological results of all purchased compounds (pharmacophore selection);
Table S4. Biological results of all purchased compounds (hit validation); Table S5. Biological data and docking
scores of the non-amidine literature inhibitors; Table S6. Pharmacophore based virtual screening of commercial
databases; Table S7. Biological data and docking scores of the thiopheneamidine inhibitors; Table S8. Parameters of
the common pharmacophore models; Scheme S1. Selected bioisosteric replacements for amidines and guanidines,
generated by Bioster 4.0.
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